Alexis R. Ogdie, MD, MSCE
Rheumatology
Accepting new patients
Sees patients age 18 and up
Penn Rheumatology Perelman
Schedule onlineCall 215-662-2454
Penn Medicine Provider

About me

  • Director, Center for Clinical Epidemiology and Biostatistics
  • Director, Penn Psoriatic Arthritis and Spondyloarthritis Program
  • Professor of Medicine (Rheumatology) at the Hospital of the University of Pennsylvania
  • Associate Professor of Epidemiology in Biostatistics and Epidemiology
  • Professor of Biostatistics and Epidemiology

Dr. Ogdie's research program is focused on inflammatory arthritis (IA) including psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and rheumatoid arthritis (RA). The mission of her research program is to improve outcomes in IA by accelerating diagnosis, increasing the focus on meaningful, patient-centered outcomes, and developing and advancing methods for precision medicine. Dr. Ogdie is an expert in the care of patients with IA, Director of the Penn Psoriatic Arthritis and Spondyloarthritis Program and Director of the Penn Center for Clinical Epidemiology and Biostatistics.

Her areas of expertise include epidemiology and pharmacoepidemiology, biostatistical methods for observational studies (e.g., complex time to event modeling, prediction modeling), outcome measures (e.g., qualitative and quantitative/psychometric assessment), clinical trial design and more general qualitative methods (e.g., survey, focus group and interview studies). Her recent work has focused on a) pragmatic trial design and implementation including the recent launch of a first head-to-head pragmatic trial in PsA (EVOLUTION, NCT05669833); b) trials aimed at improving outcomes in PsA through holistic care including a trial to test Dietary Interventions in PsA (DIPSA, NCT04180904), and a new single arm trial to address whole patient care as a novel care paradigm in rheumatology (funded by a Rheumatology Research Foundation) and c) identifying risk factors for development of PsA among patients with psoriasis.

Education and training

  • Medical School: Georgetown University School of Medicine
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

227 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

November 2025
very good experience
November 2025
caring and knowledgeable
November 2025
always a good experience
November 2025
very knowledgeable in her field and always ready to solve concerns

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Ogdie is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Gladman DD, Eder L, Selmi C, Mease PJ, Ogdie A, Lozenski K, Adamson E, Sharaf M, Rampakakis E, Pina Vegas L, Coates LC. Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials , Rheumatol Ther: 2025

Thrastardottir T, Bjornsson AH, Ogdie A, Hauksdottir A, Kristinsson SY, Gudbjornsson B, Love TJ; ICEBIO. Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study , J Rheumatol: 2025

Ogdie A, Middaugh N, Blachley T, Bourgeois T, Ling YL, Mundayat R, Fallon L, Masri KR, Mease PJ. Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry , Rheumatol Ther: 2025

Gossec L, Balanescu A, D'Agostino MA, Ogdie A, Sewerin P, Deng Y, Shi L, Sugimoto Y, Zhong S, Xing Y, Lippe R, Kishimoto M. Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials , Arthritis Res Ther: 2025

McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF. Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial , Nat Med: 2025

Landzberg E, Ogdie A, Yarnell C, Harhay MO, Yehya N. Observational studies of early versus late salvage therapies in critical care exhibit intrinsic selection bias: two meta-analyses , Crit Care, 29: 2025,411

Armstrong AW, Mburu S, Gondo GC, Kornyeyeva E, Frade S, Ogdie A. Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study , Drugs Real World Outcomes: 2025

Mayer SE, Kluberg SA, Spence O, Oraichi D, Seifert H, Ali O, Yun H, Simon AL, Ko JS, Hugh C, Her M, Shattuck K, Jamal-Allial A, Djibo DA, Daniels K, Ma Q, McMahill-Walraven CN, Ogilvie RP, Palmsten K, Selvan M, Ziyadeh N, Ogdie A, George MD. Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA , RMD Open, 11: 2025,e005839

Wu A, Zhang A, Guo Y, Liu J, Yang DM, Chada LP, Ogdie A, Reddy SM, Gottlieb AB, Scher JU, Merola JF. Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis , JAMA Dermatol: 2025

Coates LC, Blanco R, Behrens F, Ogdie A, Van den Bosch F, Ranza R, Klionsky Y, Soliman AM, Chen M, Coombs D, Shi L, Urbanik JR, Iyile T, Lippe R, Gossec L. Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies , RMD Open, 11: 2025,e005522